Extended Data Figure 2: Acquired-mTOR mutations promote resistance to mTOR inhibitors in MDA-MB-468 cells
From: Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
a, b, Dose-dependent cell growth inhibition of the MDA-MB-468 cells expressing green fluorescent protein (GFP), wild-type mTOR or different mTOR variants (A2034V, F2108L and M2327I) upon rapamycin (a) or AZD8055 treatment (b). Cells were pre-treated for 24 h with doxycycline (1 μg ml−1) to induce the expression of exogenous mTOR. The cell growth was determined as described in Fig. 1d. c–e, MDA-MB-468 cells expressing GFP, wild-type mTOR or different mTOR variants were treated with different concentrations of rapamycin (c), AZD8055 (d) or MLN0128 (e) for 4 h. Immunoblot analyses were performed on mTOR effectors. All cellular experiments were repeated at least three times.
